Nerve Damage

InventHelp Presents Construction Carrying Pad (DNV-290)

Retrieved on: 
Monday, March 21, 2022
Multimedia, Shoulder, Ninth Street, Injury, DEPT, Sale, Nerve Damage, PIPE, Building material

He invented the PLUMBER'S PIPE PAD to fulfill the need for a shoulder device to easily and safely carry plumbing pipe or other construction materials.

Key Points: 
  • He invented the PLUMBER'S PIPE PAD to fulfill the need for a shoulder device to easily and safely carry plumbing pipe or other construction materials.
  • This device would enhance a worker's ability to successfully carry materials over the shoulder while eliminating the object from digging into the body.
  • Additionally, this allows workers to carry heavy objects longer distances and prevent injuries to the shoulder and upper back.
  • The original design was submitted to the Denver sales office of InventHelp.

DGAP-News: Evotec receives € 3 m milestone payment for Bayer starting Phase II clinical development of DNP programme

Retrieved on: 
Monday, March 21, 2022
Nociception, Company, LinkedIn, Therapy, NASDAQ, Neurology, MDAX, Diabetes, News, DGAP, Frankfurt Stock Exchange, Research, Biotechnology, ESG, BAY, ISIN, Phase II, Quality of life, Safety, Twitter, Mark (given name), Brain, BDKRB1, Science, DNP, Bayer, EVO, Nerve Damage, Patient, Phase, Security (finance), Pharmaceutical industry, Fine chemical, Evotec

DNP is a common chronic condition associated with nerve damage caused by high blood sugar levels in diabetic patients.

Key Points: 
  • DNP is a common chronic condition associated with nerve damage caused by high blood sugar levels in diabetic patients.
  • DNP may be triggered through the slightest touch upon which the body sends unprompted pain signals to the brain.
  • Bayer has initiated a Phase II clinical trial to evaluate the safety and efficacy of BAY 2395840 in patients with DNP compared to placebo.
  • Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are excited that Bayer is moving ahead with the Phase II clinical development of an asset from our multi-target research alliance.

Acasti Pharma CEO to Present at the 32nd Annual Oppenheimer Healthcare Conference on March 16th

Retrieved on: 
Wednesday, March 9, 2022
NASDAQ, Compliance, Bleeding, Marketing, Neuropathic pain, SAH, FDA, A-T, ACST, Nerve Damage, SubArachnoid Space, Subarachnoid hemorrhage, PHN, Brain, GLOBE, Oppenheimer, Postherpetic neuralgia, TSX, Skull, RSVP, Disability, Pharmaceutical industry, Ataxia–telangiectasia

LAVAL, Quebec, March 09, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan DAlvise, President and Chief Executive Officer of Acasti Pharma will be presenting at the 32nd Annual Oppenheimer Healthcare conference being held virtually March 15-17, 2022.

Key Points: 
  • LAVAL, Quebec, March 09, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan DAlvise, President and Chief Executive Officer of Acasti Pharma will be presenting at the 32nd Annual Oppenheimer Healthcare conference being held virtually March 15-17, 2022.
  • A webcast of the Companys presentation can be accessed here: https://wsw.com/webcast/oppenheimer20/acst/2765322 and on the investor relations section of Acastis website at acastipharma.com/en/investors .
  • Management will also be participating in one-on-one meetings with qualified members of the investor community throughout the conference.
  • Acasti is a specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.

Acasti Pharma Celebrates Rare Disease Day

Retrieved on: 
Monday, February 28, 2022
GLOBE, Nerve Damage, TSX, Compliance, Postherpetic neuralgia, Calendar, Movement, PHN, Risk, Securities Exchange Act of 1934, Rare Disease Day, Water, Pharmacokinetics, Disability, Security (finance), NASDAQ, Diagnosis, Awareness, COVID-19, Company, European Organisation for Rare Diseases, Interest, SAH, U.S. Securities and Exchange Commission, Bleeding, Empowering Patients First Act, ACST, Neuropathic pain, Ataxia–telangiectasia, Nimodipine, SubArachnoid Space, PK, Skull, Brain, Subarachnoid hemorrhage, FDA, Securities Act of 1933, EURORDIS, Patient, Marketing, Degenerative disease, Drug Quality and Security Act, Private Securities Litigation Reform Act, Solution, A-T, Pharmaceutical industry, Public relations

LAVAL, Qubec, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), today recognizes and celebrates Rare Disease Day (February 28), as established by the European Organisation for Rare Diseases.

Key Points: 
  • LAVAL, Qubec, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), today recognizes and celebrates Rare Disease Day (February 28), as established by the European Organisation for Rare Diseases.
  • Rare Disease Day is the globally coordinated movement on rare diseases, working towards equity in social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare disease.
  • Since its creation in 2008, Rare Disease Day has played a critical part in building an international rare disease community that is multi-disease, global and diverse but united in purpose.
  • Rare Disease Day is observed every year on 28 February (or 29 in leap years) the rarest day of the year.

Acasti Pharma Inc. CEO, Jan D'Alvise, Is Featured on The Stock Day Podcast

Retrieved on: 
Tuesday, February 22, 2022
Nerve Damage, Compliance, Postherpetic neuralgia, PHN, Risk, Pharma, Securities Exchange Act of 1934, Disability, Security (finance), NASDAQ, COVID-19, Interview, Company, Sale, Safety, Disease, Grace, SAH, U.S. Securities and Exchange Commission, Bleeding, ACST, Subarachnoid hemorrhage, Neuropathic pain, SubArachnoid Space, PK, Skull, Brain, FDA, Securities Act of 1933, Patient, Marketing, Drug Quality and Security Act, Private Securities Litigation Reform Act, A-T, Pharmaceutical industry, Ataxia–telangiectasia

Phoenix, Arizona--(Newsfile Corp. - February 22, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.

Key Points: 
  • Phoenix, Arizona--(Newsfile Corp. - February 22, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.
  • CEO of the Company, Jan D'Alvise, joined Stock Day host Everett Jolly.
  • To hear the entire interview with Jan D'Alvise, follow the link to the podcast here: https://audioboom.com/posts/8035884-acasti-pharma-inc-ceo-jan-d-alvise-i... .
  • Acasti is a specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.

Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer, at 2022 ASCO GU Annual Meeting

Retrieved on: 
Thursday, February 17, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cytopenia, Society, Global, Patient, Cancer, CEO, RPF, Ritonavir, Fear, Risk, MCRPC, Hair loss, Prostate, Prostate cancer, Medication, Quality of life, Nerve Damage, Safety, Neutrophil, IV, Division, CRPC, MD, Peripheral neuropathy, Docetaxel, Internal medicine, PSA, Taxane, Disease management, Growth, University, COVID-19, ASCO, ORR, Hair, Prostate-specific antigen, Pharmaceutical industry, Neutropenia

Modra Pharmaceuticals (Modra) today announced positive data from its Phase IIb trial evaluating its boosted oral taxane therapeutic, ModraDoc006/r, in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) compared to the standard-of-care, the IV chemotherapy docetaxel.

Key Points: 
  • Modra Pharmaceuticals (Modra) today announced positive data from its Phase IIb trial evaluating its boosted oral taxane therapeutic, ModraDoc006/r, in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) compared to the standard-of-care, the IV chemotherapy docetaxel.
  • Our goal with ModraDoc006/r is to offer a better tolerated, effective and more convenient oral taxane therapeutic to patients with prostate cancer, including those who cannot tolerate or otherwise access IV therapy.
  • Based on the currently reported compelling data, we are planning out the next development steps for ModraDoc006/r, including a pivotal study.
  • Modras lead program completed a Phase 2b clinical study in prostate cancer, resulting in positive date further supporting the delivery, bioavailability and tolerability of its novel approach.

Alkem licenses technology from Harvard University, aiming to treat ischemic injury and vascular diseases

Retrieved on: 
Thursday, February 10, 2022
GLOBE, Industry, OTD, Biological engineering, Mooney, Vascular disease, Skin, Harvard John A. Paulson School of Engineering and Applied Sciences, Laboratory, Harvard Medical School, Toxicity, Amputation, Foot, Conditional sentence, Wyss, FDA, Alkem Laboratories, Technology, Diabetic neuropathy, Injury, Patient, Moyamoya disease, Regeneration, Applied science, PAD, SEAS, Ischemia, Hospital, Muscle, Wyss Institute for Biologically Inspired Engineering, Research, Drug development, Harvard University, Nerve Damage, Wyss Institute, Pharmaceutical industry, Vaccine, Engineering

Alkem plans to apply its drug development and manufacturing capability to advance this technology from bench to bedside through the application of efficient translational, pre-clinical, and clinical models.

Key Points: 
  • Alkem plans to apply its drug development and manufacturing capability to advance this technology from bench to bedside through the application of efficient translational, pre-clinical, and clinical models.
  • This license agreement with Harvard enables us to harness an innovation with great clinical potential, identified and nurtured by the Wyss Institute, to bring novel treatments to market.
  • Ingber is theJudahFolkman Professor of Vascular Biologyat Harvard Medical School and Boston Childrens Hospital, and Professor of Bioengineering at Harvard SEAS.
  • This precision, novel enabling technology went through a thorough diligence process with Alkem, who were impressed by its potential use in populations worldwide to treat multiple ischemic conditions.

Acasti Pharma Schedules Third Quarter Fiscal 2022 Business Update Conference Call

Retrieved on: 
Monday, February 7, 2022
NASDAQ, Private Securities Litigation Reform Act, Securities Act of 1933, GLOBE, U.S. Securities and Exchange Commission, Telephone, ACST, PHN, PK, Postherpetic neuralgia, Marketing, Subarachnoid hemorrhage, SubArachnoid Space, FDA, Security (finance), Compliance, Brain, Securities Exchange Act of 1934, Risk, A-T, TSX, Disability, SAH, Nerve Damage, Bleeding, Neuropathic pain, Skull, COVID-19, Pharmaceutical industry, Ataxia–telangiectasia

LAVAL, Quebec, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (NASDAQ: ACST and TSX-V: ACST), today announced that it will host a conference call at 1:00 PM Eastern Time on Monday, February 14, 2022 to discuss the Companys corporate progress and other developments, as well as financial results for the fiscal 2022 third quarter ended December 31, 2021.

Key Points: 
  • LAVAL, Quebec, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (NASDAQ: ACST and TSX-V: ACST), today announced that it will host a conference call at 1:00 PM Eastern Time on Monday, February 14, 2022 to discuss the Companys corporate progress and other developments, as well as financial results for the fiscal 2022 third quarter ended December 31, 2021.
  • A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2210/44486 or on the Companys Investor Relations section of the website: https://www.acastipharma.com/investors/ .
  • A webcast replay will be available on the Companys Investors News/Events section of the website ( https://www.acastipharma.com/investors/ ) through February 14, 2023.
  • Acasti is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.

Eisana Corp and Cortex Design announce collaboration to develop medical device for cancer patients

Retrieved on: 
Tuesday, January 25, 2022
Oncology, Medical Devices, Health, Other Health, General Health, Biotechnology, Survival, Disorder, Quality of life, Patient, Chemotherapy-induced peripheral neuropathy, FDA, Pain, ISO 9001:2015, CIPN, Cancer, Corporation, Nerve Damage, Doctor of Philosophy, MBA, CEO, Pharmaceutical industry, Cortex, Eisana Corporation, Cortex Design, EISANA CORPORATION, CORTEX DESIGN

Providing these devices will allow us to completely redefine how cancer patients experience treatment by making chemotherapy far less devastating.

Key Points: 
  • Providing these devices will allow us to completely redefine how cancer patients experience treatment by making chemotherapy far less devastating.
  • About Eisana Corporation: Eisana was founded in 2020 in Houston, Texas to develop affordable, tech-enabled products to prevent the most devastating side effects of cancer treatment.
  • About Cortex Design: Toronto-based Cortex Design is an award-winning ISO 9001:2015 design firm specialized in developing and commercializing innovative medical and consumer products.
  • Cortexs Design for Commercialization methodology allows clients to support and/or augment their internal resources to de-risk their product design and launch exceptional products.

Global Vertebral Compression Fracture Devices Market (2021 to 2027) - Growing Geriatric Population is Expected to Spur Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 11, 2022
Health, Surgery, Medical Supplies, Medical Devices, Scoliosis, Fracture, Ageing, Scoliosis and Spinal Disorders, Vertebral compression fracture, Inflammation, United Nations, Muscle, Arthritis, COVID-19, Travel, Nerve Damage, Adoption, Population, Back pain, Growth, Degenerative disc disease, Augmented fifth, Spine, Spinal disc herniation, Human, Osteoporosis, Hypoesthesia, Movement, Neck pain, Time, Bleeding, Acceleration, Skin, Spinal cord, Pelvic fracture, Trauma, Risk, Neoplasm, Bone loss, Spondylosis, Kyphosis, Walking, Hematoma, Infection, Vertebra, Prevalence, Ankylosing spondylitis, Degenerative disease, Dentistry, Poultry, Vertebral augmentation

The imposed lockdown, ban on travel, and restrictions on movements across the world have impacted the manufacturing and imports & exports of vertebral compression fracture devices.

Key Points: 
  • The imposed lockdown, ban on travel, and restrictions on movements across the world have impacted the manufacturing and imports & exports of vertebral compression fracture devices.
  • Thus, the COVID-19 pandemic has negatively affected the growth of the vertebral compression fracture devices market across the globe.
  • Due to this increased population, the demand for vertebral compression fracture devices is also growing across the globe.
  • This is expected to further hamper the growth of the vertebral compression fracture devices market over the forecast period.